Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
- Conditions
- Renal Cell Carcinoma Stage IV
- Interventions
- Other: mHealth Smart Phone ApplicationBehavioral: eHEALS digital literacy testBehavioral: Weekly QuizBehavioral: European Organization for the Research and Treatment of Cancer Quality of Life QuestionnaireBehavioral: Patient Post Intervention Survey
- Registration Number
- NCT05579847
- Brief Summary
The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 20
- Patients with Stage IV Renal Cell Carcinoma
- Within 3 weeks from starting combination immune checkpoint blockade with tyrosine kinase inhibitor or multikinase inhibitor
- Estimated survival of 6 months or more
- Able to read and speak English
- Unable to read or speak English
- Enrolled in another clinical trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Study Participants Weekly Quiz Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application. Study Participants eHEALS digital literacy test Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application. Study Participants mHealth Smart Phone Application Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application. Study Participants Patient Post Intervention Survey Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application. Study Participants European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
- Primary Outcome Measures
Name Time Method Acceptability of Smart Phone Application at 6 months Patient's acceptability of the smart phone application for education will be captured in the patient post education survey.
- Secondary Outcome Measures
Name Time Method Efficacy of Smart Phone Application -Quality of Life at 6 months Efficacy of the smart phone application on patient quality of life will be assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) scores.
Efficacy of Smart Phone Application - Patient Knowledge Weekly, beginning at baseline to month 6 Efficacy of the smart phone application on patient knowledge of their diagnosis and treatment will be assessed by weekly true/false quizzes.
Trial Locations
- Locations (1)
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States